Ireland· IE-PA-EU/1/17/1245/003
PREVYMIS 240 mg Concentrate for solution for infusion
A antivirals for systemic use product containing letermovir, registered in Ireland by Merck Sharp & Dohme BV.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- LETERMOVIR
- Manufacturer
- Merck Sharp & Dohme BV
- Country
- Ireland (IE)
- ATC code
- J05
- ATC class
- ANTIVIRALS FOR SYSTEMIC USE
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/17/1245/003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Letermovir in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayPrevymisMerck Sharp & Dohme B.V. (1)
- BelgiumPrevymis 240 mgMerck Sharp & Dohme
- CzechiaPREVYMISMerck Sharp & Dohme B.V., Haarlem
- FinlandPREVYMISMerck Sharp & Dohme B.V.
- IcelandPrevymisMerck Sharp & Dohme B.V.*
- SwedenPREVYMIS 240 mg Koncentrat till infusionsvätska, lösningMerck Sharp & Dohme BV
- SwitzerlandPrevymis 120 mg, GranulatMSD Merck Sharp & Dohme AG
- FrancePREVYMIS 120 mg, granulés en sachetMERCK SHARP & DOHME (PAYS-BAS)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Prevymis
- Liechtenstein · Prevymis
- Norway · Prevymis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fac4377b-8da5-44d8-9f0f-54252cd0f0ac GET /v1/drugs/fac4377b-8da5-44d8-9f0f-54252cd0f0ac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use",
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05"
],
"strength": null,
"pa_number": "EU/1/17/1245/003",
"substances": [
"LETERMOVIR"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "08/01/2018",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about letermovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.